-
High dimensional data moves from bench to bedside with focus on individualized care
Manoj Bhasin, PhD, MS, will unveil some of the latest developments in multi-dimensional and spatial single-cell omics.
-
Results from head-to-head trial of four type 2 diabetes agents to be presented
“We hope to give a comprehensive, comparative view of which drugs do what and in which people,” said GRADE Principal Investigator David Nathan, MD.
-
SURPASS clinical trials may lead to the next chapter in incretin-based therapies
New, detailed results of the first Phase 3 SURPASS clinical trials involving tirzepatide will be presented in a dedicated symposium. “The glucose-lowering and weight reductions of this dual incretin receptor agonist are unprecedented,” said Julio Rosenstock, MD.
-
Popular review session will summarize year of diabetes advances
The session offers a broad look at advancements in basic, clinical, and translational sciences, putting into context recent research and the future of the field. Speakers include Maureen Gannon, PhD, and Jay S. Skyler, MD, MACP.
-
New agents poised to transform management of heart failure
Michelle M. Kittleson, MD, PhD, and Nasrien E. Ibrahim, MD, will discuss how recent trial results can be leveraged to save lives with angiotensin receptor-neprilysin inhibition and SGLT2 inhibitors.
-
Experts will discuss strategies to minimize COVID-19 risks for diabetes patients
The 2021 Diabetes Care Symposium, featuring speakers Matthew C. Riddle, MD, and Paresh Dandona, MD, PhD, will examine how to mitigate the threefold risk for severe COVID-19 infection among diabetes patients.